Recap: ThermoGenesis Holdings Q1 Earnings

Shares of ThermoGenesis Holdings THMO decreased in after-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were up 85.59% year over year to ($0.16), which missed the estimate of ($0.13).

Revenue of $1,517,000 decreased by 52.59% from the same period last year, which missed the estimate of $2,660,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: May 13, 2021

Time: 04:30 PM

ET Webcast URL: https://78449.choruscall.com/dataconf/productusers/thmo/mediaframe/44454/indexr.html

Technicals

52-week high: $11.70

52-week low: $1.92

Price action over last quarter: down 15.19%

Company Description

ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!